* If you want to update the article please login/register
"Objectives Patients of schizophrenia have a high risk of self-harm. " Random forest models for self-harm were developed to identify the individuals with self-harm and anticipate future self-harm incidents. Over a 36-month period, 187 patients with FES had one or more self-harm events. Positive psychotic symptoms soared from the second year to second, with depression contributing the most to self-harm prediction during the first year. Patients with DSH were identified using a random forest model with all static data and symptoms of instability, a good area under the receiver operating characteristic curve for identifying patients with DSH. Conclusions The following results show the importance of the constant association of depressive and positive psychotic disorders with self-harm, as well as the possibility of self-harm prediction in FES using longitudinal clinical data. ".
Source link: https://europepmc.org/article/MED/35689554
"Methods We recruited 54 first-episode schizophrenia patients, 52 BD patients, 35 MDD patients, and 54 healthy controls from inpatient and outpatient clinics, as well as 54 healthy controls. " The Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale, manic signs using the Young Mania Rating Scale, and depressive signs using the 17 item-Hamilton Depression Rating Scale were used to determine psychotic signs. Executive performance was also measured using the computerized Cambridge Neuropsychological Test Automated Battery, which was distributed to all participants. There were no significant differences between the three patient groups in their ability to distinguish between the three patient groups. In FES and BD groups, lower oxytocin and higher substance p were associated with more psychotic signs. In both three patient groups, u03b2-endorphin was associated with early morning wakening symptom. Conclusions The results of our study show that circulating neuropeptides have the ability to distinguish severe mental disorders from controls.
Source link: https://europepmc.org/article/PPR/PPR503964
"Objective: Patients with schizophrenia may have signs of hostility. " Changes in Positive and Negative Syndrome Scale hostility item and PANSS-Excited Component scores from baseline to week six were assessed post hoc using a mixed-effects system for repeated measures adjusted for key PANSS-Positive signs and the presence of somnolence or akathisia. Results: Among 442 patients with baseline PANSS hostility item score > 1, a week 6 LSM change from baseline was much higher with HP-3070 versus placebo for 7. 6 mg/24 h and 3. 8 mg/24 h, with similar results for 7. 6 mg/24 h after adjusting for covariates. PANSS-EC week 6 LSM CFB was higher for HP-3070 7. 6 mg/24 h and 3. 8 mg/24 h than placebo, with similar findings reported in patients with baseline hostility item score > 1" or higher.
Source link: https://europepmc.org/article/MED/35687858
"However, medical causes underlying schizophrenia's negative effects are still poorly understood, and diagnosis options for negative symptoms are limited. " We found that the schizophrenia group had higher modularity, clustering coefficient, and typical path length, as well as lower rich links compared to controls, demonstrating tighter nodes within modules but not so well integrated with nodes in other modules in schizophrenia. Modularity increases the incidence of higher negative symptoms in patients with schizophrenia, but not with cognitive impairments in patients with schizophrenia, suggesting that update in modularity may be specific to overall negative symptoms.
Source link: https://europepmc.org/article/MED/35661912
"Although depressive symptoms are common in patients with schizophrenia, most SCZ patients are not well managed," says the author. Patients with comorbid depression may have triggered inflammatory responses, and celecoxib, a COX2 inhibitor, can reduce inflammation and improve depression treatment. We therefore set out to investigate the efficacy of celecoxib augmentation for depressive symptoms in SCZ patients and its potential connection with BDNF serum levels and two BDNF genotypes. Our results showed that SCZ patients had lower BDNF levels than healthy controls. In SCZ patients, the BDNF gene rs10835210 was associated with SCZ sensitivity, positive signs, and BDNF serum levels. In addition, patients in the BDNF rs10835210 CC group demonstrated significantly more improvement in depressive symptoms in comparison to the A allele carrier group. Our findings show that COX2 inhibitors may be a promising therapeutic agent for the relief of comorbid depressive symptoms in FEDN SCZ patients.
Source link: https://europepmc.org/article/PPR/PPR500878
"We wanted to clarify the relationship between the single nucleotide polymorphisms in the COMT gene and the severity of positive and negative symptoms. " In the quantitative analyses, thirteen studies were qualitatively evaluated, including 4443 adult patients with schizophrenia. Quantitative studies were performed on acutely sick and clinically stable patient subgroups based on the varying genotypes of rs4680 SNP. In patients who were rs4680 Met homozygous, relative to Val/Met heterozygotes only in acutely ill samples, but our findings showed that the severity of negative symptoms was higher in patients who were ill. The difference in negative symptoms did not suggest any significant moderator effect, according to meta-regression results. Symptom profiles for general psychopathology, positive, negative, and total psychotic symptoms were also similar between Val homozygotes and Met carriers, with positive, negative, and total psychotic symptom levels being similar. The COMT rs4680 Met allele was found to have higher incidences of acutely ill patients, according to our findings.
Source link: https://europepmc.org/article/MED/35642295
"The current study seeks to show how to use precision nomothetic technology to investigate the interconnections between schizophrenia's negative symptoms, cognitive abnormalities, and biomarkers of schizophrenia. We review our findings from various study groups of patients with schizophrenia and show how Partial Least Squares path analysis can be used to analyze these complicated relationships. Both the negative and PHEMFP subdomains lack discriminant validity, although a single latent construct may be extracted from the 6 negative and 6 PHEMFP subdomains, dubbed overall severity of schizophrenia. The general cognitive decline index has a common latent factor that may be extracted from neurocognitive test results, including executive functions, and semantic and episodic memory. According to PLS' report, the effects of neuroimmunotoxic pathways on OSOS are partially mediated by the G-CoDe, and that those pathways have also direct effects on OSOS. ".
Source link: https://europepmc.org/article/PPR/PPR498633
"We built two brain functional networks based on the positive and negative correlations between positive symptom scores and brain connectivity in drug-naive patients with first-episode schizophrenia using a machine-learning approach. " Network strengths were then compared to FES participants, people at a genetic risk of schizophrenia, and healthy controls. The negatively associated network in FES had less cross-subnetwork links and concentrated on the sensory/somatomotor hand -Cingulo opercular task control network, the DMN, and a visual network with significantly reduced connectivity in the COTC-SMH network. In addition, FES's connectivity strengths of the right supplementary motor area and the right precentral gyrus were reduced. This is the first study to establish two brain networks associated with positive symptoms in FES using CPM in FES, to the best of our knowledge. ".
Source link: https://europepmc.org/article/MED/35656348
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions